Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

National Safety Council and Pacira BioSciences Partner to Launch an Employee-Based Program Focused on Opioid Use and Misuse

06/16/2022 | 08:02am EDT

Initiative educates employees and their family members on the importance of preventing opioid misuse and addiction

TAMPA, Fla. and ITASCA, Ill., June 16, 2022 (GLOBE NEWSWIRE) -- The National Safety Council, America’s leading nonprofit safety advocate, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the launch of their partnership and the Connect2Prevent program. Connect2Prevent is an innovative employee-family educational program that increases awareness and prevention of opioid addiction.

NSC created a comprehensive curriculum designed to educate employees on the risks associated with opioids and provide them with the tools to have meaningful discussions with adolescent family members. The curriculum includes 10-12 weeks of engaging lessons on opioids, addiction, stigma, risk factors for substance use, refusal skills, harm reduction, how to talk to doctors about opioid alternatives and more. The lessons provide easy-to-understand education, action steps and evidence-based tools to connect and communicate with teens.

“As an organization committed to eliminating the leading causes of preventable death, we recognize the opportunity education presents to curtail the tragic impact of opioid addiction and misuse,” said Jenny Burke, vice president of impairment practice at NSC. “We are committed to saving lives by providing information and resources about the risks of opioids and opioid misuse to help employees and their loved ones have thoughtful conversations on this topic. Our partnership with Pacira is a significant step in the right direction toward supporting these efforts.”

Connect2Prevent uses a 2Gen approach, giving employees information about opioids and how to communicate and connect with their teens. The program has the potential to impact families across generations. Connect2Prevent supports employees and their families through this curriculum and incorporates input and ideas provided by teens for how the adults in their lives can talk with them about this important topic into the lessons.

“Children who use prescription opioids before 12th grade have a 33% higher risk of opioid misuse as an adult,” said Dave Stack, chief executive officer and chairman of Pacira BioSciences, Inc. “Education is a critical component in the fight against the opioid crisis, and raising awareness to the availability of non-opioid options to treat both acute and chronic pain is central to the Pacira mission to improve patient care.”

The program will be piloted this summer, with participants receiving weekly lessons. Each lesson includes educational information, action steps and ways to connect and communicate with teens, including evidence-based motivational interviewing strategies. Pilot participants will have the opportunity to review and provide feedback on the program before it is launched publicly in 2023.

About the National Safety Council
The National Safety Council is America's leading nonprofit safety advocate and has been for more than 100 years. As a mission-based organization, we work to eliminate the leading causes of preventable death and injury, focusing our efforts on the workplace, roadway, and impairment. We create a culture of safety to not only keep people safer at work, but also beyond the workplace so they can live their fullest lives.

About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera°®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com

Media Contact:
Coyne Public Relations
Kristin Capone, (973) 588-2108
kcapone@coynepr.com

NSC Media Contacts:
Erin McDermott, (630) 775-2037
Senior Manager, Communications

Jennifer Schallmoser
Media Relations Coordinator, (630) 775-2307
media@nsc.org


All news about PACIRA BIOSCIENCES, INC.
09/27Pacira BioSciences, Sevaredent Partner Over Expanded Access to Exparel for Patients Und..
MT
09/27Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expand..
GL
09/27Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expand..
AQ
09/27Sevaredent Sourcing Solutions and Pacira BioSciences, Inc. Collaborate to Provide Expan..
CI
09/21Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a S..
GL
09/21Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a S..
GL
09/21Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A S..
CI
09/20Pacira BioSciences Receives Positive Opinion for Post-Surgical Pain Treatment in Childr..
MT
09/20Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pa..
GL
09/20Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment ..
CI
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 691 M - -
Net income 2022 86,9 M - -
Net Debt 2022 510 M - -
P/E ratio 2022 32,3x
Yield 2022 -
Capitalization 2 486 M 2 486 M -
EV / Sales 2022 4,33x
EV / Sales 2023 3,39x
Nbr of Employees 697
Free-Float 98,8%
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 54,24 $
Average target price 78,20 $
Spread / Average Target 44,2%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.-9.86%2 481
JOHNSON & JOHNSON-3.82%437 390
ELI LILLY AND COMPANY21.06%317 719
ROCHE HOLDING AG-14.15%273 173
ABBVIE INC.6.79%255 667
PFIZER, INC.-25.22%249 357